Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China (Q28478918)

30

0 references

Feng Sun

object named as

Feng Sun

27

0 references

author name string

Penghui Shang

1

0 references

Yinyin Xia

2

0 references

Feiying Liu

3

0 references

Xiaomeng Wang

4

0 references

Yanli Yuan

5

0 references

Daiyu Hu

6

0 references

Dehua Tu

7

0 references

Yixin Chen

8

0 references

Peiyuan Deng

9

0 references

Shiming Cheng

10

0 references

Lin Zhou

11

0 references

Yu Ma

12

0 references

Lizhen Zhu

13

0 references

Weiwei Gao

14

0 references

Hongyuan Wang

15

0 references

Dafang Chen

16

0 references

Li Yang

17

0 references

Pingping He

18

0 references

Shanshan Wu

19

0 references

Shaowen Tang

20

0 references

Xiaozhen Lv

21

0 references

Zheng Shu

22

0 references

Yuan Zhang

23

0 references

Zhirong Yang

24

0 references

Yan Chen

25

0 references

Na Li

26

0 references

Xiaoting Li

28

0 references

Yingjian He

29

0 references

Siyan Zhan

Creative Commons Attribution 4.0 International

31

0 references

language of work or name

English

0 references

publication date

2011

0 references

published in

PLOS One

0 references

volume

6

0 references

page(s)

e21836

0 references

issue

7

0 references

copyright license

start time

5 July 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

An assessment of factors contributing to treatment adherence and knowledge of TB transmission among patients on TB treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3130045

The effect of tuberculosis control in China

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3130045

Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3130045

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3130045

Design of the anti-tuberculosis drugs induced adverse reactions in China National Tuberculosis Prevention and Control Scheme Study (ADACS).

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3130045

Incidence, clinical and epidemiological risk factors, and outcome of drug-induced hepatitis due to antituberculous agents in new tuberculosis cases.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3130045

Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3130045

Antituberculosis drug-induced hepatotoxicity: concise up-to-date review

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3130045

An official ATS statement: hepatotoxicity of antituberculosis therapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3130045

Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3130045

Epidemiology and individual susceptibility to adverse drug reactions affecting the liver

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3130045

Frequency and type of reactions to antituberculosis drugs: observations in routine treatment

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3130045

Criteria of drug-induced liver disorders. Report of an international consensus meeting

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3130045

The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3130045

Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3130045

Hepatotoxicity from rifampin plus pyrazinamide: lessons for policymakers and messages for care providers

2 June 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0021836

Hepatotoxicity of pyrazinamide: cohort and case-control analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0021836

Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0021836

Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0021836

Evaluation of patient-related factors associated with causality, preventability, predictability and severity of hepatotoxicity during antituberculosis [correction of antituberclosis] treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0021836

Tuberculosis management in Europe. Task Force of the European Respiratory Society (ERS), the World Health Organisation (WHO) and the International Union against Tuberculosis and Lung Disease (IUATLD) Europe Region.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0021836

Non-adherence to tuberculosis treatment in the eastern Tarai of Nepal

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21750735